Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
AbCellera Biologics Inc. has appointed Andrew Booth chief financial officer. Previously, Booth was vice president of instrumentation, chief financial officer and chief commercial officer at STEMCELL Technologies.
Alpha Tau Medical
Alpha Tau Medical has named Robert Den chief medical officer. Den is currently an associate professor of radiation oncology, cancer biology and urology at Thomas Jefferson University.
Lynne LeSauteur was named vice president of immunochemistry and immunology at Altasciences. LeSauteur most recently was director of downstream processing and analytics as well as program leader of biologics and biomanufacturing for the Human Health Therapeutics Research Center at the National Research Council of Canada.
Aprecia, the 3DP Pharmaceutical Company, named Kirk Donaldson vice president of business development and alliance management. Donaldson most recently served as associate director of account management at MEDPACE.
Auris Medical Holding
Elmar Scharli has been named chief financial officer at Auris Medical Holding Ltd. Scharli was the founder and chief executive officer of Ante Treuhand AG, a Swiss fiduciary company.
Azelis has appointed Ron Rosenberg as its first ever group technical innovation director. Rosenberg was the technical director of the Americas with Azelis since 2014.
Stefan Grass has been named chief medical and technology officer at Bactiguard. Grass previously served as the medical affairs manager for the Nordic region at CSL Behring.
Bionik Laboratories Corp. has appointed Loren Wass as chief commercial officer. Wass was most recently vice president of sales and reimbursement at ReWalk Robotic.
Renee Ryan has been named chief executive officer at Cala Health. Previously, Ryan served as the head of venture investments at Johnson & Johnson.
Crescendo Biologics Ltd. has named Stewart Kay chief business officer. Previously, Kay served as senior director of transactions in the world-wide business development group at GlaxoSmithKline.
Ross Muken has been named chief financial officer at Click Therapeutics, Inc. Muken most recently served as senior managing director and partner at Evercore ISI.
Farcast Biosciences has appointed Maneesh Arora as president and chief executive officer. Previously, Arora served as the chief operating officer and director at Exact Sciences.
India-based gvk bioSciences has appointed Sudhir Singh chief operating officer. Singh held the position of executive vice president, discovery services at the company since 2013.
Kelly Londy has been named chief executive officer at Innoblative Designs. Londy was previously CEO and executive officer at Lumicell.
Jim Lalonde has been named lead strategic business and portfolio developer for Inscripta, Inc. Lalonde’s most recently appointment was with Codexis, where he was senior vice president of research and development.
Juha Lauren has been appointed chief business officer at Kallyope. Lauren was a senior director of business development and research and development strategy at Regeneron Pharmaceuticals.
Mark Nuttall has been named chief business officer at Kintai Therapeutics. Nuttall previously was the chief business officer at Kymera Therapeutics.
Locana has named Kathie Bishop chief science officer. Bishop was most recently chief science officer at Otonomy.
Medispend has named Craig Hauben chief executive officer. Hauben most recently served as the executive vice president of coding business at Ciox Health.
Kevin Duffy has been named vice president of medical affairs and external collaborations at Maryland-based Northwest Biotherapies. Duffy most recently served as the research scientific director in the Keytruda program at Merck.
ObsEva has added to its executive committee with Elizabeth Garner named chief medical officer. Garner most recently owned and was the president of KNI Health Consultants in addition to her role as chief medical officer at Agile Therapeutics.
Dennis Donohoe was named chief medical officer of Orchestra BioMed. Previously, Donohoe was the part-time chief medical officer for Orchestra BioMed’s focal therapies group and its predecessor, Caliber Therapeutics.
Prometheus Biosciences, Inc.
Previously known as Precision IBD, Prometheus Biosciences, Inc. has changed its name and appointed Mark McKenna as chief executive officer. McKenna previously served as president of Salix Pharmaceuticals.
Robocath has appointed Lucien Goffart as chief executive officer. Previously, Goffart was business unit manager for France at Boston Scientific.
Brian Castagna was named chief information officer at Boston-based Seven Bridges. Previously Castagna served as the director of information security at Oracle.
Jonathan Guarino has been named chief financial officer at Solgenix. Guarino was previously corporate controller for Hepion Pharmaceuticals.
Somatus has appointed Jon Kunkle chief financial officer. Previously, Kunkle was head of finance and chief financial officer at Kaiser Permanente.
Stealth BioTherapeutics has appointed Robert Weiskopf chief financial officer. Weiskopf most recently served as chief financial officer and treasurer at ArQule.
Step Pharma has appointed Andrew Parker as chief executive officer. Previously, Parker served as executive vice president and chief science officer at Zealand Pharma.
Synlogic has named Richard Riese chief medical officer and Michael Slater head of regulatory affairs. Previously, Riese served as the vice president of clinical development at Alnylam and Slater served as the head of regulatory affairs and development operations at Merrimack Pharmaceuticals.
Lori Batta has been named chief commercial officer at TMRW. Batta was most recently chief commercial officer at next generation women’s health company Celmatix.
Joseph Larsen has been named vice president of strategic portfolio development at VenatoRx Pharmaceuticals. Larsen was previously senior vice president of life sciences at Strategic Marketing Innovations.
Verge Genomics has appointed Jane Rhodes chief business officer. Rhodes was most recently vice president of business development and corporate strategy at FORMA Therapeutics.
Peter Baker was named chief commercial officer at Xellia Pharmaceuticals. Baker previously was the national accounts lead for Xellia North America.